-
公开(公告)号：US11687256B2
公开(公告)日：2023-06-27
申请号：US17858664
申请日：2022-07-06
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai
IPC: A61K48/00 , G06F3/06 , A61K38/17 , A61P35/00 , A61K45/06 , C07K14/705 , A61K39/395 , G06F11/30 , A61K39/00
CPC classification number: G06F3/0629 , A61K38/177 , A61K39/3955 , A61K45/06 , A61K48/00 , A61P35/00 , C07K14/70575 , G06F11/3051 , A61K2039/505 , G06F11/3093
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
公开(公告)号：US11003366B2
公开(公告)日：2021-05-11
申请号：US16542381
申请日：2019-08-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
公开(公告)号：US10379767B2
公开(公告)日：2019-08-13
申请号：US16207575
申请日：2018-12-03
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
公开(公告)号：US10335486B2
公开(公告)日：2019-07-02
申请号：US15996146
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Susannah Hewitt , Ailin Bai , Stephen G. Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K39/39 , A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K45/06 , A61K31/713 , A61K39/00 , A61P35/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
公开(公告)号：US11660341B2
公开(公告)日：2023-05-30
申请号：US17202829
申请日：2021-03-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Susannah Hewitt , Ailin Bai , Stephen G. Hoge , Vladimir Presnyak , Iain McFadyen , Kerry Benenato , Ellalahewage Sathyajith Kumarasinghe
IPC: A61K48/00 , A61K39/395 , C07K14/54 , C07K14/705 , C07K16/28 , A61K39/39 , A61K45/06 , A61K31/713 , A61K39/00 , A61P35/00
CPC classification number: A61K39/39558 , A61K31/713 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K48/005 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/705 , C07K14/70503 , C07K14/70532 , C07K14/70575 , C07K14/70596 , C07K16/2818 , A61K2039/505 , A61K2039/51 , A61K2039/53 , A61K2039/585 , A61P35/00 , C07K2317/76 , C07K2319/30 , C07K2319/32 , A61K31/713 , A61K2300/00
Abstract: The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer. The disclosure provides compositions, and methods for their preparation, manufacture, and therapeutic use, wherein those compositions comprise at least two polynucleotides (e.g., mRNAs) in combination wherein the at least two polynucleotides are selected from the group consisting of (i) a polynucleotide encoding an immune response primer (e.g., IL23), (ii) a polynucleotide encoding an immune response co-stimulatory signal (e.g., OX40L), (iii) a polynucleotide encoding a checkpoint inhibitor (e.g., an anti CTLA-4 antibody), and, (iv) a combination thereof. The therapeutic methods disclosed herein comprise, e.g., the administration of a combination therapy disclosed herein for the treatment of cancer, e.g., by reducing the size of a tumor or inhibiting the growth of a tumor, in a subject in need thereof. In some aspects, the combination therapies disclosed herein disclosed are administered intratumorally.
-
Patent Agency Ranking
公开(公告)号：US10383951B2
公开(公告)日：2019-08-20
申请号：US16225989
申请日：2018-12-19
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai
IPC: A61K48/00 , A61K38/17 , A61P35/00 , A61K45/06 , C07K14/705
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
公开(公告)号：US20190185529A1
公开(公告)日：2019-06-20
申请号：US16036170
申请日：2018-07-16
Applicant: ModernaTX, Inc.
Inventor： Stephen G. Hoge , Tirtha Chakraborty , Joshua P. Frederick , Matthias John , Antonin De Fougerolles
IPC: C07K14/47 , A61K31/711 , C12N15/85 , C12N15/113 , A61K48/00 , A61K31/7105
CPC classification number: C07K14/47 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K48/0058 , C12N15/113 , C12N15/85 , C12N2310/141
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.
-
公开(公告)号：US11185510B2
公开(公告)日：2021-11-30
申请号：US16543102
申请日：2019-08-16
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai , Vladimir Presnyak , Stephen G. Hoge , Kerry Benenato , Iain McFadyen , Ellalahewage Sathyajith Kumarasinghe , Susannah Hewitt
IPC: A61K38/20 , A61K9/51 , A61K48/00 , A61K38/17 , A61K9/00 , A61K39/39 , A61K45/06 , A61K9/127 , C07K14/54 , C07K14/545 , C07K14/705 , A61K31/7088 , A61K31/7115 , A61P35/00 , A61K39/395 , A61K39/00 , B82Y5/00 , C12N15/88
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
-
公开(公告)号：US10815291B2
公开(公告)日：2020-10-27
申请号：US16009717
申请日：2018-06-15
Applicant: ModernaTX, Inc.
Inventor： Joseph Beene Bolen , Joshua P. Frederick
IPC: C07K14/705 , A61K31/7115 , A61K48/00
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
-
公开(公告)号：US20180318385A1
公开(公告)日：2018-11-08
申请号：US15996140
申请日：2018-06-01
Applicant: ModernaTX, Inc.
Inventor： Joshua P. Frederick , Ailin Bai
CPC classification number: A61K38/177 , A61K31/7088 , A61K45/06 , A61P35/00 , C07K14/70575
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.047 seconds)
